Role of the genetic polymorphism of p53 (codon 72) gene in colorectal cancer;Estudo do polimorfismo genético no gene p53 (códon 72) em câncer colorretal

Arquivos de Gastroenterologia

Volumn 43, Issue 1, 2006, Pages 8-13

  De Lima, Jacqueline Miranda ^b   Serafim, Patrícia Valéria Pereira ^b   Da Silva, Ismael Dale Cotrim Guerreiro ^b   Forones, Nora Manoukian ^a  

^a Disciplina de Gastroenterologia   (Brazil)

^b NONE

Author keywords

Colorectal neoplasms; Genes; p53; Polymorphism (genetics); Prognosis

Indexed keywords

ALCOHOL; ARGININE; PROLINE; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CHROMOSOME SUBSTITUTION; CODON; COLORECTAL CANCER; CONTROLLED STUDY; GENDER; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PREVALENCE; TOBACCO;

EID: 33646708733     PISSN: 00042803     EISSN: 16784219     Source Type: Journal    
DOI: 10.1590/s0004-28032006000100005     Document Type: Article

References (27)

1. Brasileiro-Filho G, Guimarães RC, Bogliolo L. Distúrbios do crescimento e da diferenciação celular. In: Brasileiro-Filho G, editor. Patologia clínica. Rio de Janeiro: Guanabara Koogan; 1998. p.148-92.
2. Brose MS, Smyrk T, Weber B, Lynch HT. Genetic predisposition to cancer - cancer etiology. In: Bast RC Jr, Kufe DW, Pollock RE, Weichselbaum RR, Holland JF, Frei E, editors. Cancer medicine. Ontario, Canada: BC Becker; 2000. p.168-84.
3. Cotti GCC, Santos FPS, Sebastianes FM, Habr-Gama A, Seid VE, Martino RB. Genética do câncer colorretal. Rev Med. (São Paulo) 2000;79:45-64.
4. Gemignani F, Moreno V, Landi S, Moullan N, Chabrier A, Gutiérrez-Enríquez S, Hall J, Guino E, Peinado MA, Capella G, Canzian F. A TP53 polymorphism is associated with increased risk of colorectal cancer and with reduced levels of TP53 mRNA. Oncogene. 2004;23:1954-6.
5. Gomes DC, Oliveira JFP, Duarte KS, Santos MO, Rebelo MS, Reis RS. Estimativas da incidência e mortalidade por câncer no Brasil. Ministério da Saúde. Instituto Nacional de Câncer (INCA). Site: http://www.inca.gov.br/01/2005.
6. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 1994;54:4855-78.
7. Harris CC, Hollstein M. Clinical implication of the p53 tumor suppressor gene. N Engl J Med. 1993;329:318-27.
8. Kietthubthew S, Sriplung H, Au WWW, Ishida T. The p53 codon 72 polymorphism and risk of oral cancer in southern Thailand. Asian Pac J Cancer Prev. 2003;4:209-14.
9. Lane DP. Cancer. p53, guardian of the genome. Nature. 1992;358:15-6.
10. Langerod A, Bukholm IR, Bregard A, Lonning PE, Andersen TI, Rognum TO, Meling GI, Lothe RA, Borresen-Dale AL. The TP53 codon 72 polymorphism may affect the function of TP53 mutations in breast carcinomas but not in colorectal carcinomas. Cancer Epidemiol Biomarkers Prev. 2002;11:1684-8.
11. Lodish H, Berk A, Zipursky SL, Matsudaira P, Baltimore D, Darnell J. Análise genética em biologia molecular. In: Nader HB, editor. Biologia celular e molecular. Rio de Janeiro: Revinter; 2002. p.255-93.
12. Lynch HT, Lynch JF. Genetics of colonic cancer. Digestion. 1998;59:481-92.
13. Marin MC, Jost CA, Brooks LA, Irwin MS, O'Nions J, Tidy JA, James N, McGregor JM, Harwood CA; Yulug IG, Vousden KH, Allday MJ, Gusterson B, Ikawa S, Hinds PW, Crook T, Kaelin WG. A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat Genet. 2000;25:47-54.
14. National Center for Biotechnology Information. Site: www.ncbi.nlm.nih. gov/-jan/2005.
15. Nussbaum RL, McInnes RR, Willard HF. Variação genética em indivíduos: mutação e polimorfismo. In: Motta PA, editor. Genética médica. Rio de Janeiro: Guanabara Koogan; 2002. p.69-82.
16. Papadakis ED, Soulitzis N, Spandidos DA. Association of p53 codon 72 polymorphism with advanced lung cancer: the Arg allele is preferentially retained in tumours arising in Arg/Pro germline heterozygotes. Br J Cancer. 2002;87:1013-8.
17. Papadakis EN, Dokianakis DN, Spandidos DA. p53 codon 72 polymorphism as risk factor in the development of breast cancer. Mol Cell Biol. 2000;3:389-92.
18. Sayhan N, Yazici H, Budak M, Dalay N. p53 codon 72 genotypes in colon cancer. Association with human papillomavirus infection. Res Commun Mol Pathol Pharmacol. 2001;109:25-34.
19. Schneider-Stock R, Boltze C, Peters B, Szibor R, Landt O, Meyer F, Roessner A. Selective loss of codon 72 proline p53 and frequent mutational inactivation of the retained arginine allele in colorectal cancer. Neoplasia. 2004;6:529-35.
20. Shaw P, Bovey R, Tardy S, Sahli R, Sordat B, Costa J. Induction of apoptosis by wild type p53 in a human colon tumor-derived cell-line. Proc Natl Acad Sci USA. 1992;89:4495-9.
21. Smith ML, Fornace AJ Jr. The two faces of tumor suppressor p53. Am J Pathol. 1996;148:1092-100.
22. Soulitzis N, Sourvinos G, Dokianakis DN, Spandidos DA. p53 codon 72 polymorphisms and its association with bladder cancer. Cancer Lett. 2002;179:175-83.
23. Tada M, Furuuchi K, Kaneda M, Matsumoto J, Takahashi M, Hirai A, Mitsumoto Y, Iggo RD, Moriuchi T. Inactivate the remaining p53 allele or the alternate p73? Preferential selection on the Arg72 polymorphism in cancers with recessive p53 mutants but not transdominant mutants. Carcinogenesis. 2001;22:515-7.
24. Thomas M, Kalita A, Labrecque S, Pim D, Banks L, Matlashewski G. Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cel Biol. 1999;19:1325-8.
25. Vogelstein B, Fearon ER, Kern SE, Hamilton SR, Preisinger AC, Nakamura Y, White R. Allelotype of colorectal carcinomas. Science. 1989;244:207-11.
26. Xiong Y. p21 is a universal inhibi for of cyclina kinases. Nature. 1993;366:701-4.
27. Yamaguschi MD, Sugano K, Fukayama N, Nakashima Y, Saotome K, Yokoayama T, Yokota T, Ohkura H. Polymerase chain reaction-based approaches for detection of allelic loss in the p53 tumor suppressor gene in colon neoplasms. Am J Gastroenterol. 1997;92:307-12.